Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Cardiovascular disease is the leading cause of death in patients with diabetes mellitus and represents a persistent risk that is inextricably linked to the diabetic disease state. The growing number of United States Food and Drug Administration - approved antidiabetic agents provides a wide range of therapeutic options, both as monotherapy and combination therapy, for treating hyperglycemia in patients with type 2 diabetes. Long-term clinical experience with many of these agents has revealed nonglycemic effects on lipid levels, inflammation, and cardiovascular function. Although some of these agents can improve cardiovascular disease risk in patients with diabetes, others may increase the risk and may be prohibited from use in certain populations. Thus, the effect of antidiabetic agents on cardiovascular health and safety must be considered when selecting the most appropriate therapy. A review of the current literature was undertaken to examine the effects of antidiabetic agents on cardiovascular disease, and with the help of illustrative patient case examples, useful information is provided for clinicians to individualize therapy for patients with type 2 diabetes.

Original languageEnglish
Pages (from-to)193-206
Number of pages14
JournalPharmacotherapy
Volume28
Issue number2
DOIs
StatePublished - Feb 2008

Fingerprint

Hypoglycemic Agents
Type 2 Diabetes Mellitus
Comorbidity
Cardiovascular Diseases
Therapeutics
United States Food and Drug Administration
Hyperglycemia
Cause of Death
Diabetes Mellitus
Inflammation
Lipids
Safety
Health
Population

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities. / Malesker, Mark A.

In: Pharmacotherapy, Vol. 28, No. 2, 02.2008, p. 193-206.

Research output: Contribution to journalReview article

@article{aed2ef70c4b548c0bec5496f240c59a3,
title = "Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities",
abstract = "Cardiovascular disease is the leading cause of death in patients with diabetes mellitus and represents a persistent risk that is inextricably linked to the diabetic disease state. The growing number of United States Food and Drug Administration - approved antidiabetic agents provides a wide range of therapeutic options, both as monotherapy and combination therapy, for treating hyperglycemia in patients with type 2 diabetes. Long-term clinical experience with many of these agents has revealed nonglycemic effects on lipid levels, inflammation, and cardiovascular function. Although some of these agents can improve cardiovascular disease risk in patients with diabetes, others may increase the risk and may be prohibited from use in certain populations. Thus, the effect of antidiabetic agents on cardiovascular health and safety must be considered when selecting the most appropriate therapy. A review of the current literature was undertaken to examine the effects of antidiabetic agents on cardiovascular disease, and with the help of illustrative patient case examples, useful information is provided for clinicians to individualize therapy for patients with type 2 diabetes.",
author = "Malesker, {Mark A.}",
year = "2008",
month = "2",
doi = "10.1592/phco.28.2.193",
language = "English",
volume = "28",
pages = "193--206",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities

AU - Malesker, Mark A.

PY - 2008/2

Y1 - 2008/2

N2 - Cardiovascular disease is the leading cause of death in patients with diabetes mellitus and represents a persistent risk that is inextricably linked to the diabetic disease state. The growing number of United States Food and Drug Administration - approved antidiabetic agents provides a wide range of therapeutic options, both as monotherapy and combination therapy, for treating hyperglycemia in patients with type 2 diabetes. Long-term clinical experience with many of these agents has revealed nonglycemic effects on lipid levels, inflammation, and cardiovascular function. Although some of these agents can improve cardiovascular disease risk in patients with diabetes, others may increase the risk and may be prohibited from use in certain populations. Thus, the effect of antidiabetic agents on cardiovascular health and safety must be considered when selecting the most appropriate therapy. A review of the current literature was undertaken to examine the effects of antidiabetic agents on cardiovascular disease, and with the help of illustrative patient case examples, useful information is provided for clinicians to individualize therapy for patients with type 2 diabetes.

AB - Cardiovascular disease is the leading cause of death in patients with diabetes mellitus and represents a persistent risk that is inextricably linked to the diabetic disease state. The growing number of United States Food and Drug Administration - approved antidiabetic agents provides a wide range of therapeutic options, both as monotherapy and combination therapy, for treating hyperglycemia in patients with type 2 diabetes. Long-term clinical experience with many of these agents has revealed nonglycemic effects on lipid levels, inflammation, and cardiovascular function. Although some of these agents can improve cardiovascular disease risk in patients with diabetes, others may increase the risk and may be prohibited from use in certain populations. Thus, the effect of antidiabetic agents on cardiovascular health and safety must be considered when selecting the most appropriate therapy. A review of the current literature was undertaken to examine the effects of antidiabetic agents on cardiovascular disease, and with the help of illustrative patient case examples, useful information is provided for clinicians to individualize therapy for patients with type 2 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=38849124241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38849124241&partnerID=8YFLogxK

U2 - 10.1592/phco.28.2.193

DO - 10.1592/phco.28.2.193

M3 - Review article

VL - 28

SP - 193

EP - 206

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 2

ER -